Inovio Pharmaceuticals (INO)
Inovio Pharmaceuticals Revenues: 1.60M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
INO Revenues Rankings
| Overall | 3rd percentile | 4285 of 4432 |
| Sector | 15th percentile | 399 of 470 in Healthcare |
| Industry | 25th percentile | 98 of 132 in Biotechnology |
INO Revenues Range, Past 5 Years
| Minimum | 0.327M | Dec 2008 |
| Maximum | 3.646M | Sep 2009 |
| Average | 1.654M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these INO related companies
INO News
@Urbane_Gorilla $INO yes. we should get some results in 2nd half 2012 coming up soon! may get the needle moving positive again!
about 13 days ago by BiopharmaPro
about 13 days ago by BiopharmaPro
@BiopharmaPro $INO looks like it really wants to tag 0.35 again. No shorts? Hmmm.. Anyway, we need an H1N1 scare to run it up a bit.
about 13 days ago by Urbane_Gorilla
about 13 days ago by Urbane_Gorilla
@Urbane_Gorilla @Yongecity $INO is a much longer term play. phase I data didn't even move it! I expect phase 2 or phase 3 data to push it!!
about 13 days ago by BiopharmaPro
about 13 days ago by BiopharmaPro
Inovio (INO) Reports Encouraging Data for SynCon Vaccine in Generating HAI Titers
May 16, 6:49AM Street Insider
May 16, 6:49AM Street Insider
@Yongecity But I didn't check to see if maybe $INO isn't in the same business as something else that might pop..Pin action.
about 15 days ago by Urbane_Gorilla
about 15 days ago by Urbane_Gorilla
@Yongecity $INO..Same issues with the market, but on a break, 0.60 and 0.70. But I don;t see any catalysts. No PDUFA, FDA or even ASCO
about 15 days ago by Urbane_Gorilla
about 15 days ago by Urbane_Gorilla
$INO Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer. http://stks.co/3au6
about 29 days ago by BiopharmaPro
about 29 days ago by BiopharmaPro
$INO filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3FaW
about 54 days ago by MarketBrief
about 54 days ago by MarketBrief
Inovio Appoints Retired Merck Vaccines President Dr. Adel Mahmoud to its Board of Directors
Mar 27, 4:00AM PR Newswire
Mar 27, 4:00AM PR Newswire
From Earlier: Inovio Receives U.S. Patent for SynCon H1N1 Influenza Universal Vaccine
Mar 26, 7:23AM Benzinga
Mar 26, 7:23AM Benzinga
Inovio Pharmaceuticals (INO) Posts Narrwer than Expected Q4 Loss; Revs Light
Mar 15, 4:22PM Street Insider
Mar 15, 4:22PM Street Insider
Inovio Pharmaceuticals Reports 2011 Fourth Quarter and Year-End Financial Results
Mar 15, 4:20PM PR Newswire
Mar 15, 4:20PM PR Newswire
Inovio Pharmaceuticals (INO) Reports Successful Demonstration of RNA Drug Delivery via Electroporation
Feb 22, 6:57AM Street Insider
Feb 22, 6:57AM Street Insider
Inovio Researchers Successfully Demonstrate RNA Drug Delivery via Electroporation
Feb 22, 4:00AM PR Newswire
Feb 22, 4:00AM PR Newswire
Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
Jan 11, 4:00AM PR Newswire
Jan 11, 4:00AM PR Newswire
Inovio Pharmaceuticals to Present at Biotech Showcase Investor Conference
Jan 05, 4:00AM PR Newswire
Jan 05, 4:00AM PR Newswire
Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
Jan 04, 4:00AM PR Newswire
Jan 04, 4:00AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| INO | 0.44 | -0.01 | -2.22% | 59.39M |
| ININ | 25.91 | -0.25 | -0.96% | 500.44M |
| ING | 5.80 | -0.25 | -4.13% | 22.88B |
| IMN | 5.63 | -0.05 | -0.88% | 217.71M |
| IMMU | 3.365 | -0.04 | -1.32% | 257.56M |
| IMMR | 5.62 | +0.23 | +4.27% | 150.27M |
| IMKTA | 15.27 | -0.35 | -2.24% | 379.10M |
| IMI | 6.74 | +0.01 | +0.15% | |
| IMH | 2.02 | -0.01 | -0.49% | 15.80M |
| IMGN | 14.34 | -0.13 | -0.90% | 1.111B |
